INTRODUCTION: The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) highlights the urgent need for novel therapeutic strategies. Immune checkpoint inhibitors (ICIs) seem to be ineffective in most PDAC studies. Therefore, we conducted an open-label, multicenter phase 1/2 study (CA209-9KH) to evaluate the safety of stereotactic radiotherapy (SRT) and sequential ICI therapy in PDAC, as well as to validate the efficacy of this regimen as a potential activator of antitumor immunity. METHODS: Patients aged ≥ 18 years with unresectable non-metastatic PDAC following four FOLFIRINOX induction cycles were included. Treatment comprised SRT (4 × 8 Gy) and sequential nivolumab administration until disease progression or unacceptable toxicity. The primary endpoints were safety and toxicity assessment. Secondary endpoints included progression-free survival (PFS), overall survival (OS), biomarker evaluation, and quality of life (QoL) analysis. RESULTS: Twenty-two patients were screened, with 15 enrolled. Eleven (median) nivolumab cycles were administered. SRT demonstrated low and clinically nonsignificant toxicity, whereas nivolumab toxicity aligned with prior safety profiles, without grade 4-5 events observed. Three patients discontinued therapy owing to toxicity. Median PFS and OS were 8.1 and 13.0 months, respectively, with 12-month PFS and OS rates of 0% and 66.7%, respectively, and a 24-month OS rate of 8.9%. Biomarker levels correlated with clinical or radiological disease control. Patient-reported QoL remained acceptable, deteriorating with disease progression. CONCLUSION: SRT and nivolumab therapy exhibited manageable toxicity profiles consistent with previous findings; however, long-term treatment responses were not achieved with this regimen in locally advanced PDAC. Another strategy to trigger antitumor immunity in PDAC needs to be sought. TRIAL REGISTRATION: EudraCT: 2017-003404-52; ClinicalTrials.gov: NCT04098432.

1st Faculty of Medicine Charles University Prague Czech Republic

Department of Oncology and Radiotherapy University Hospital Hradec Králové Sokolská 581 50005 Hradec Králové Czech Republic

Department of Oncology Thomayer University Hospital Prague Czech Republic

Department of Oncology University Hospital Olomouc Olomouc Czech Republic

Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Faculty of Medicine in Hradec Králové Charles University Prague Czech Republic

The Fingerland Department of Pathology University Hospital Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Global Cancer Observatory. Available at: https://www-dep.iarc.fr/. Accessed November 21, 2023.

Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160:744–54. 10.1053/j.gastro.2020.10.007. PubMed

Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice [online]. Masaryk University. Available at: http://www.svod.cz. Accessed April 13, 2024.

Yasinzai AQK, Tareen B, Tracy K, Jamil N, Khan M, Ullah H, et al. Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive US population-based study. Clin Transl Oncol. 2024. 10.1007/s12094-024-03484-7. (Online ahead of print). PubMed

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. 10.3322/caac.21708. PubMed

Cabasag CJ, Arnold M, Rutherford M, Bardot A, Ferlay J, Morgan E, et al. Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. Br J Cancer. 2022;126:1774–82. 10.1038/s41416-022-01752-3. PubMed PMC

Mazur R, Trna J. Principles of palliative and supportive care in pancreatic cancer: a review. Biomedicines. 2023;11:2690. 10.3390/biomedicines11102690. PubMed PMC

NCCN clinical practice guidelines in oncology, NCCN guidelines version 1.2024. Pancreatic adenocarcinoma. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed December 27, 2023.

Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987–1002. 10.1016/j.annonc.2023.08.009. PubMed

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. 10.1056/NEJMoa1200694. PubMed PMC

O’Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a Phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1431–8. 10.1001/jamaoncol.2019.1588. PubMed PMC

Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist. 2020;25:e808–15. 10.1634/theoncologist.2019-0473. PubMed PMC

Li X, Gulati M, Larson AC, Solheim JC, Jain M, Kumar S, et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022;86:14–27. 10.1016/j.semcancer.2022.08.009. PubMed PMC

Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World J Gastroenterol. 2021;27:6775–93. 10.3748/wjg.v27.i40.6775. PubMed PMC

Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. 2015;33:7415–22. 10.1016/j.vaccine.2015.05.105. PubMed PMC

Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31. 10.1056/NEJMoa1112824. PubMed PMC

Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365–72. 10.1158/2326-6066.CIR-13-0115. PubMed PMC

D’Andrea MA, Reddy GK. Systemic effects of radiation therapy-induced abscopal responses in patients with advanced lung cancer. Oncology. 2021;99:1–14. 10.1159/000510287. PubMed

Janopaul-Naylor JR, Shen Y, Qian DC, Buchwald ZS. The abscopal effect: a review of pre-clinical and clinical advances. Int J Mol Sci. 2021;22:11061. 10.3390/ijms222011061. PubMed PMC

Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, et al. Randomized Phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J Clin Oncol. 2022;40:3180–9. 10.1200/JCO.21.02511. PubMed

Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2:1124–35. 10.1038/s43018-021-00269-7. PubMed PMC

Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, et al. Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res. 2020;26:2318–26. 10.1158/1078-0432.CCR-19-3624. PubMed PMC

Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(Supplement):S10–9. 10.1016/j.ijrobp.2009.07.1754. PubMed PMC

U.S.Department of Health and Human Services. National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 Published. (v4.03: June 14, 2010). 2009. [cited 11/21/2023]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52. 10.1016/S1470-2045(17)30074-8. PubMed PMC

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. 10.1056/NEJMoa1011923. PubMed

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. 10.1056/NEJMoa1304369. PubMed PMC

Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105–12. 10.1200/JCO.2011.34.8904. PubMed PMC

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317–26. 10.1016/S1470-2045(13)70021-4. PubMed PMC

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315:1844–53. 10.1001/jama.2016.4324. PubMed

Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, et al. FOLFIRINOX for locally advanced pancreatic cancer: results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Pancreatology. 2019;19:296–301. 10.1016/j.pan.2019.01.001. PubMed

Yoo C, Hwang I, Song TJ, Lee SS, Jeong JH, Park DH, et al. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Ther Adv Med Oncol. 2020;12:1758835920953294. 10.1177/1758835920953294. PubMed PMC

Roselló S, Pizzo C, Huerta M, Muñoz E, Aliaga R, Vera A, et al. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. ESMO Open. 2020;5: e000929. 10.1136/esmoopen-2020-000929. PubMed PMC

Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5:285–94. 10.1016/S2468-1253(19)30327-9. PubMed

Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, et al. The survival benefit of chemoradiotherapy following Induction chemotherapy with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancers (Basel). 2021;13:4733. 10.3390/cancers13184733. PubMed PMC

Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:128–38. 10.1016/S2468-1253(20)30330-7. PubMed

Shi Z, Yang J, Kong W, Qiu X, Lu C, Liu J, et al. Use of nab-paclitaxel Plus gemcitabine followed by hypofractionated tomotherapy with simultaneous integrated boost in patients with locally advanced pancreatic cancer. Front Oncol. 2022;12: 782730. 10.3389/fonc.2022.782730. PubMed PMC

Su YY, Chiu YF, Li CP, Yang SH, Lin J, Lin SJ, et al. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. Br J Cancer. 2022;126:1018–26. 10.1038/s41416-021-01649-7. PubMed PMC

McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O’Reilly EM, et al. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. J Surg Oncol. 2022;125:425–36. 10.1002/jso.26735. PubMed PMC

Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135–44. 10.1016/j.ejca.2022.12.014. PubMed

Guo S, Wang Z. Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies. Front Oncol. 2024;14:1349308. 10.3389/fonc.2024.1349308. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT04098432